US FDA approves Ionis Pharma's Tryngolza to treat adults living with familial ... - Pharmabiz.com
Ionis Pharmaceuticals announced FDA approval of Tryngolza (olezarsen), the first treatment for familial chylomicronemia syndrome (FCS), reducing triglycerides and acute pancreatitis risk. Tryngolza, self-administered monthly, showed significant reductions in triglyceride levels and AP events in a Phase 3 study, with a favorable safety profile. This marks a pivotal moment for Ionis, transitioning to a commercial-stage biotech company.
Highlighted Terms
Related News
Ionis Pharmaceuticals announced FDA approval of Tryngolza (olezarsen), the first treatment for familial chylomicronemia syndrome (FCS), reducing triglycerides and acute pancreatitis risk. Tryngolza, self-administered monthly, showed significant reductions in triglyceride levels and AP events in a Phase 3 study, with a favorable safety profile. This marks a pivotal moment for Ionis, transitioning to a commercial-stage biotech company.